Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

14.49 +1.05 (+7.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ARS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings
Via Benzinga
ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray
Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
Via Investor's Business Daily
ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024
ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
Via Benzinga
ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Where ARS Pharmaceuticals Stands With Analysts
Via Benzinga
ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect 
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Analyst Ratings For ARS Pharmaceuticals
Via Benzinga
Looking Into ARS Pharmaceuticals's Recent Short Interest
Via Benzinga
ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned
Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
Via Benzinga
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
Via Benzinga
Exposures Product Safety
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
SPRY Stock Earnings: ARS Pharmaceuticals Meets EPS for Q1 2024
SPRY stock results show that ARS Pharmaceuticals met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Plunge In March
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
SPRY Stock Earnings: ARS Pharmaceuticals Beats EPS for Q4 2023
SPRY stock results show that ARS Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024
U.S. equities market is rallying, but there are still interesting investments to make, especially for these strong-buy stocks under $10. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.